Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GSK NYSE:RDY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGSKGSK$40.88+2.1%$38.59$31.72▼$44.19$81.57B0.533.24 million shs9.42 million shsRDYDr. Reddy's Laboratories$14.61+2.5%$14.35$12.26▼$16.19$11.91B0.32832,223 shs679,598 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGSKGSK+2.06%+5.04%+8.26%-1.70%-6.94%RDYDr. Reddy's Laboratories+2.42%+3.58%+5.75%-8.26%-8.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGSKGSK$40.88+2.1%$38.59$31.72▼$44.19$81.57B0.533.24 million shs9.42 million shsRDYDr. Reddy's Laboratories$14.61+2.5%$14.35$12.26▼$16.19$11.91B0.32832,223 shs679,598 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGSKGSK+2.06%+5.04%+8.26%-1.70%-6.94%RDYDr. Reddy's Laboratories+2.42%+3.58%+5.75%-8.26%-8.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGSKGSK 1.86Reduce$37.38-8.57% DownsideRDYDr. Reddy's Laboratories 2.80Moderate Buy$16.9516.02% UpsideCurrent Analyst Ratings BreakdownLatest GSK and RDY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025RDYDr. Reddy's LaboratoriesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGSKGSK$40.10B2.08$5.69 per share7.18$8.07 per share5.07RDYDr. Reddy's Laboratories$3.81B3.20$1.06 per share13.81$4.73 per share3.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGSKGSK$3.29B$2.1618.938.792.0010.81%49.22%11.31%10/29/2025 (Estimated)RDYDr. Reddy's Laboratories$663M$0.6622.1417.825.7616.99%17.25%11.63%11/4/2025 (Estimated)Latest GSK and RDY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025GSKGSK$1.12$1.23+$0.11$0.94$7.92 billion$10.64 billion7/23/2025Q1 25/26RDYDr. Reddy's Laboratories$0.18$0.20+$0.02$0.20$88.27 billion$988.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGSKGSK$1.684.11%N/A77.78%N/ARDYDr. Reddy's Laboratories$0.070.48%N/A10.61%N/ALatest GSK and RDY DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date1/1/2100GSKGSKquarterly$0.42064.3%8/15/20258/15/202510/9/20256/30/2025RDYDr. Reddy's Laboratoriesannual$0.09150.623832253665189%7/25/20257/10/20258/6/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGSKGSK1.070.870.57RDYDr. Reddy's Laboratories0.011.891.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGSKGSK15.74%RDYDr. Reddy's Laboratories3.85%Insider OwnershipCompanyInsider OwnershipGSKGSK10.00%RDYDr. Reddy's Laboratories2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGSKGSK68,6292.04 billion1.83 billionOptionableRDYDr. Reddy's Laboratories27,811834.90 million818.20 millionOptionableGSK and RDY HeadlinesRecent News About These CompaniesDr. Reddy’s Laboratories Receives USFDA Observations at UK FacilitySeptember 8 at 12:38 PM | msn.comRoyal Bank of Canada Sells 986,447 Shares of Dr. Reddy's Laboratories Ltd $RDYSeptember 5, 2025 | marketbeat.comDr. Reddy's Laboratories Ltd $RDY Shares Sold by Northern Trust CorpSeptember 4, 2025 | marketbeat.comDr. Reddy's Laboratories Ltd $RDY Stake Lowered by OMERS ADMINISTRATION CorpSeptember 2, 2025 | marketbeat.comBNP Paribas Financial Markets Purchases 1,682,363 Shares of Dr. Reddy's Laboratories Ltd $RDYSeptember 2, 2025 | marketbeat.comOLD Mission Capital LLC Has $3.45 Million Stock Position in Dr. Reddy's Laboratories Ltd $RDYSeptember 1, 2025 | marketbeat.comHsbc Holdings PLC Sells 21,500 Shares of Dr. Reddy's Laboratories Ltd $RDYSeptember 1, 2025 | marketbeat.comDr. Reddy's Laboratories Ltd $RDY Shares Acquired by Invesco Ltd.September 1, 2025 | marketbeat.comWellington Management Group LLP Reduces Stock Holdings in Dr. Reddy's Laboratories Ltd $RDYAugust 31, 2025 | marketbeat.comJump Financial LLC Boosts Holdings in Dr. Reddy's Laboratories Ltd $RDYAugust 30, 2025 | marketbeat.comCW Advisors LLC Acquires New Position in Dr. Reddy's Laboratories Ltd $RDYAugust 30, 2025 | marketbeat.comCauseway Capital Management LLC Sells 394,866 Shares of Dr. Reddy's Laboratories Ltd $RDYAugust 28, 2025 | marketbeat.comAmerican Century Companies Inc. Increases Position in Dr. Reddy's Laboratories Ltd $RDYAugust 28, 2025 | marketbeat.comDr. Reddy’s Laboratories Secures Interim Stay on Tax Reassessment OrderAugust 26, 2025 | msn.comVanguard Group Inc. Buys 106,457 Shares of Dr. Reddy's Laboratories Ltd $RDYAugust 26, 2025 | marketbeat.comQuantbot Technologies LP Makes New $1.26 Million Investment in Dr. Reddy's Laboratories Ltd $RDYAugust 25, 2025 | marketbeat.comDeutsche Bank AG Cuts Stock Holdings in Dr. Reddy's Laboratories Ltd $RDYAugust 24, 2025 | marketbeat.comGroupama Asset Managment Buys New Position in Dr. Reddy's Laboratories Ltd $RDYAugust 23, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Trims Position in Dr. Reddy's Laboratories Ltd $RDYAugust 22, 2025 | marketbeat.comDr. Reddy's Laboratories Ltd (NYSE:RDY) Given Consensus Recommendation of "Moderate Buy" by AnalystsAugust 21, 2025 | marketbeat.comCorient IA LLC Acquires New Holdings in Dr. Reddy's Laboratories Ltd $RDYAugust 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGSK and RDY Company DescriptionsGSK NYSE:GSK$40.88 +0.83 (+2.07%) Closing price 09/9/2025 03:59 PM EasternExtended Trading$40.79 -0.09 (-0.22%) As of 09/9/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.Dr. Reddy's Laboratories NYSE:RDY$14.61 +0.35 (+2.45%) Closing price 09/9/2025 03:59 PM EasternExtended Trading$14.62 +0.01 (+0.03%) As of 09/9/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
